Current Report Filing (8-k)
February 16 2017 - 8:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 16, 2017
FibroGen, Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36740
|
|
77-0357827
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
FibroGen, Inc.
409 Illinois Street
San
Francisco, CA 94158
(Address of principal executive offices, including zip code)
(415)
978-1200
(Registrants telephone number, including area code)
Not Applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 7.01
|
Regulation FD Disclosure
|
Beginning February 16, 2017, FibroGen, Inc. (the Company)
intends to conduct meetings with existing and prospective investors and analysts in which its corporate slide presentation will be presented. A copy of the presentation materials, including a slide setting forth certain cautionary statements
intended to qualify the forward-looking statements therein, is attached as Exhibit 99.1 to this Current Report on
Form 8-K
and is incorporated herein by reference.
The information in this Item 7.01 is being furnished, not filed, pursuant to Regulation FD. Accordingly, the information in Item 7.01 of this
report will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the
information in this report is not intended to, and does not, constitute a determination or admission by the Company that the information in this report is material or complete, or that investors should consider this information before making an
investment decision with respect to any security of the Company.
Item 9.01
|
Financial Statements and Exhibits.
|
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
FibroGen, Inc. Presentation Materials dated February 16, 2017
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
F
IBRO
G
EN
, I
NC
.
|
|
|
|
Dated: February 16, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Michael Lowenstein
|
|
|
|
|
|
|
Michael Lowenstein
|
|
|
|
|
|
|
Chief Legal Counsel
|
INDEX TO EXHIBITS
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
FibroGen, Inc. Presentation Materials dated February 16, 2017
|
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024